Table 2.
(including HA-VRE from screening and clinical specimen). Results of multivariable analysis for hospital-acquired VRE cases with antibiotic use by antibiotic group (ATC-code 5-digit)
| Parameter/category | IRR | 95% CI | p-value |
|---|---|---|---|
| Ward | |||
| Medical ward | 1 = reference | ||
| Hematological/oncological ward | 4.90 | 1.8–13.3 | 0.002 |
| Intensive care unit | 5.97 | 2.83–12.60 | <.0001 |
| Surgical ward | 1.25 | 0.59–2.63 | 0.554 |
| At least one patient with community-acquired VRE on ward in the current month | 1.69 | 1.32–2.16 | <.0001 |
| Screening of all patients on admission irrespective of underlying risk factors (1 = yes) | 2.27 | 1.01–5.08 | 0.047 |
| Carbapenem (J01DH) use in the current month (per 1 DDD/100 patient-days) | 1.01 | 1.00–1.02 | 0.01 |
| Glycopetide (J01XA) use in the previous month (per 1 DDD/100 patient-days) | 1.02 | 1.01–1.04 | 0.002 |
| Year 2015 (compared to 2014) | 1.45 | 1.17–1.79 | <.0001 |
DDD Defined daily dose; IRR Incidence rate ratio; CI Confidence interval